-
1 Comment
Pharmicell Co., Ltd is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 173.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 23.4.
Pharmicell Co., Ltd's total revenue sank by 11.5% to $9B since the same quarter in the previous year.
Its net income has dropped by 70.9% to $686M since the same quarter in the previous year.
Finally, its free cash flow fell by 109.1% to $-54M since the same quarter in the previous year.
Based on the above factors, Pharmicell Co., Ltd gets an overall score of 1/5.
| Exchange | KO |
|---|---|
| Industry | Biotechnology |
| CurrencyCode | KRW |
| Sector | Healthcare |
| ISIN | KR7005690003 |
| Beta | 0.36 |
|---|---|
| Market Cap | 650B |
| PE Ratio | None |
| Target Price | 17500 |
| Dividend Yield | 0.2% |
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 005690.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
